Insider Selling: Opus Genetics (NASDAQ:IRD) COO Sells $13,653.36 in Stock

Posted by Brian Himes on Jul 28th, 2026

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) COO Joseph Schachle sold 4,644 shares of Opus Genetics stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.94, for a total value of $13,653.36. Following the transaction, the chief operating officer directly owned 291,440 shares of the company’s stock, valued at $856,833.60. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Opus Genetics Stock Performance

Shares of IRD traded up $0.12 during mid-day trading on Tuesday, reaching $3.47. The company had a trading volume of 312,042 shares, compared to its average volume of 939,716. The company has a market capitalization of $286.44 million, a price-to-earnings ratio of -2.60 and a beta of 0.55. Opus Genetics, Inc. has a 52 week low of $1.04 and a 52 week high of $5.81. The firm has a 50-day moving average price of $3.91 and a 200 day moving average price of $4.02.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%. The company had revenue of $2.16 million for the quarter, compared to the consensus estimate of $2.93 million. As a group, research analysts forecast that Opus Genetics, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Citigroup began coverage on Opus Genetics in a report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Leerink Partners started coverage on shares of Opus Genetics in a research note on Thursday, May 21st. They set an “outperform” rating and a $10.00 price target on the stock. BTIG Research restated a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a research report on Monday, July 6th. Wall Street Zen cut Opus Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Opus Genetics in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Opus Genetics currently has an average rating of “Moderate Buy” and a consensus target price of $10.77.

Get Our Latest Stock Report on IRD

Institutional Investors Weigh In On Opus Genetics

Institutional investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP purchased a new stake in Opus Genetics in the 4th quarter worth $25,000. Comerica Bank purchased a new position in Opus Genetics during the first quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in Opus Genetics in the 4th quarter worth approximately $34,000. Raymond James Financial Inc. raised its stake in shares of Opus Genetics by 95.6% in the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares during the period. Finally, Johnson Investment Counsel Inc. acquired a new position in shares of Opus Genetics during the fourth quarter worth about $40,000. 14.97% of the stock is owned by hedge funds and other institutional investors.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.